Increased incidence of rheumatoid arthritis after COVID-19
暂无分享,去创建一个
J. Anaya | M. Rojas | C. Morales | J. Salazar-Uribe | M. Munera | Mauricio J. Sarmiento | Enrique Mazenett-Granados | Juan Sebastián Marín | John Fredy Suárez | Rosalbina Pérez | J. I. Domínguez | R. Pérez
[1] M. Gershwin,et al. Molecular mimicry and autoimmunity in the time of COVID-19 , 2023, Journal of Autoimmunity.
[2] J. Ciaffi,et al. Post-Acute COVID-19 Joint Pain and New Onset of Rheumatic Musculoskeletal Diseases: A Systematic Review , 2023, Diagnostics.
[3] M. Mitreva,et al. Poly(ADP-ribose) polymerase 9 mediates early protection against Mycobacterium tuberculosis infection by regulating type I IFN production , 2023, The Journal of clinical investigation.
[4] J. Anaya,et al. Post-COVID Syndrome in Adults—An Overview , 2023, Viruses.
[5] C. Scheidt-Nave,et al. Incident autoimmune diseases in association with a SARS-CoV-2 infection: A matched cohort study , 2023, medRxiv.
[6] R. Chang,et al. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study , 2023, eClinicalMedicine.
[7] Y. Chávez,et al. Molecular mimicry among human proteinase 3 and bacterial antigens: implications for development of c-ANCA associated vasculitis , 2022, Oxford open immunology.
[8] J. Anaya,et al. Is post-COVID syndrome an autoimmune disease? , 2022, Expert review of clinical immunology.
[9] Quanzhen Li,et al. Autoimmunity is a hallmark of post-COVID syndrome , 2022, Journal of translational medicine.
[10] J. Fernández-Niño,et al. Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort , 2022, The Lancet Healthy Longevity.
[11] A. Leone,et al. Heat Shock Proteins Alterations in Rheumatoid Arthritis , 2022, International journal of molecular sciences.
[12] G. Narasimhan,et al. Potential Autoimmunity Resulting from Molecular Mimicry between SARS-CoV-2 Spike and Human Proteins , 2022, bioRxiv.
[13] Oscar J. Espinosa,et al. Characterization of the population affiliated to the subsidized health insurance scheme in Colombia: a systematic review and meta-analysis , 2022, International Journal for Equity in Health.
[14] J. Anaya,et al. Persistent Autoimmune Activation and Proinflammatory State in Post-Coronavirus Disease 2019 Syndrome , 2022, The Journal of infectious diseases.
[15] Mark S. Anderson,et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths , 2021, Science Immunology.
[16] A. Jahangiri,et al. SARS-CoV-2 Proteome Harbors Peptides Which Are Able to Trigger Autoimmunity Responses: Implications for Infection, Vaccination, and Population Coverage , 2021, Frontiers in Immunology.
[17] J. Anaya,et al. Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID-19 , 2021, Journal of Translational Autoimmunity.
[18] Y. Shoenfeld,et al. The SARS-CoV-2 as an instrumental trigger of autoimmunity , 2021, Autoimmunity Reviews.
[19] A. Barabasi,et al. PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation , 2016, Nature Communications.
[20] A. R. Gani,et al. The PARP family: insights into functional aspects of poly (ADP‐ribose) polymerase‐1 in cell growth and survival , 2016, Cell proliferation.
[21] M. Kaplan,et al. Poly‐ADP‐ribosyl polymerase‐14 promotes T helper 17 and follicular T helper development , 2015, Immunology.
[22] M. Rosado,et al. Beyond DNA repair, the immunological role of PARP‐1 and its siblings , 2013, Immunology.
[23] Y. Shoenfeld,et al. Infectious Aspects and the Etiopathogenesis of Rheumatoid Arthritis , 2010, Clinical reviews in allergy & immunology.
[24] OUP accepted manuscript , 2022, Journal of Infectious Diseases.
[25] D.,et al. Regression Models and Life-Tables , 2022 .